Pazopanib's action in bone sarcoma linked to the EWSR1-NFATC2 translocation.

Published Date: 17 Jan 2024

Titled "Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma," a new case report was released on September 20, 2023 in Oncoscience. ".".

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot